previou
studi
demonstr
concentr
glycoprotein
agp
transient
increas
asymptomat
cat
infect
felin
coronaviru
fcov
order
establish
whether
fluctuat
depend
fcov
statu
serum
concentr
agp
antifcovantibodi
titr
andor
faecal
shed
fcov
clinic
healthi
cat
catteri
differ
level
preval
fcov
infect
monitor
time
serum
agp
concentr
fluctuat
time
clinic
healthi
cat
catteri
highest
preval
felin
infecti
periton
fip
significantli
increas
outbreak
fip
studi
requir
clarifi
whether
observ
increas
agp
concentr
consequ
increas
viral
burden
protect
respons
mutat
viral
strain
nevertheless
result
present
studi
suggest
agp
might
use
monitor
fcovehost
interact
fcovendem
catteri
cute
phase
protein
app
plasma
protein
produc
hepatocyt
whose
concentr
increas
posit
app
decreas
neg
app
inflamm
stimul
cytokin
releas
inflammatori
site
van
devent
et
al
major
felin
app
glycoprotein
agp
ceron
et
al
belong
lipocalin
superfamili
group
protein
abl
bind
transport
hydrophob
molecul
gdberg
wester
previou
studi
shown
cat
affect
felin
infecti
periton
fip
lethal
diseas
cat
caus
felin
coronavirus
fcov
blood
concentr
agp
increas
duthi
et
al
howev
case
fip
record
fcovendem
catteri
nonsymptomat
cat
live
catteri
show
transient
increas
agp
concentr
suggest
appear
pathogen
fcov
strain
also
elicit
inflammatori
respons
cat
develop
clinic
sign
diseas
studi
cite
small
number
nonsymptomat
cat
examin
relationship
fluctuat
agp
level
actual
fcov
statu
cat
unclear
aim
present
studi
investig
whether
fluctuat
agp
level
nonsymptomat
fcovposit
cat
depend
fcov
statu
aim
monitor
time
serum
concentr
agp
antifcov
antibodi
titr
andor
faecal
shed
fcov
cat
live
catteri
differ
level
preval
fip
studi
perform
serum
faecal
sampl
collect
cat
group
follow
fcov
ten
anim
four
male
six
femal
age
year
randomli
select
sampl
everi
day
month
period
accord
protocol
suggest
addi
jarrett
order
identifi
carrier
shedder
group
includ
homebr
persian
cat
live
privat
household
case
fip
never
record
four
cat
one
male
three
femal
year
old
randomli
select
sampl
everi
day
month
period
group
includ
five
homebr
domest
shorthair
cat
one
male
four
femal
age
year
live
privat
household
one
case
fip
occur
year
studi
cat
sampl
everi
day
month
period
approxim
ml
blood
taken
cat
occas
place
tube
without
anticoagul
serum
obtain
centrifug
store
c
analysi
faec
spf
cat
collect
cat
enter
studi
faecal
sampl
also
collect
cat
catteri
time
blood
sampl
taken
avoid
sampl
error
cat
kept
cage
day
sampl
sampl
place
separ
plastic
envelop
transport
laboratori
cat
catteri
could
freeli
move
breed
facil
thu
possibl
monitor
faecal
excret
fcov
individu
cat
reason
fcov
statu
cat
evalu
measur
antifcov
titr
blood
regard
catteri
howev
refer
veterinarian
period
check
rtpcr
faecal
swab
mani
cat
catteri
occasion
posit
result
agp
measur
agp
measur
use
commerci
avail
radial
immunodiffus
srid
kit
tridelta
ltd
maynooth
kildar
ireland
accord
manufactur
instruct
briefli
ml
serum
sampl
standard
solut
contain
mgml
mgml
felin
agp
put
well
multiwel
srid
plate
plate
incub
room
temperatur
h
diamet
precipit
ring
measur
valu
obtain
two
standard
solut
use
design
standard
curv
valu
case
sampl
plot
extrapol
absolut
agp
level
express
mgml
cat
includ
studi
test
refer
veterinarian
felin
immunodefici
viru
fiv
felin
leukaemia
viru
felv
use
inclin
enzym
link
immunosorb
antibodi
elisa
test
snap
combo
idexx
lab
westbrook
usa
neg
case
presenc
antifcov
antibodi
titr
investig
use
indirect
immunofluoresc
test
perform
multiwel
slide
produc
univers
zurich
accord
osterhau
et
al
briefli
slide
prepar
coat
well
cell
half
infect
swine
transmiss
gastroenter
viru
tgev
serolog
crossreact
fcov
osterhau
et
al
coat
well
slide
fix
aceton
stabilis
dri
frozen
store
c
use
serolog
perform
make
twofold
dilut
serum
sampl
twenti
microlitr
dilut
appli
one
well
incub
min
c
humidifi
chamber
slide
wash
three
time
phosphat
buffer
salin
pb
dri
ml
fluoresceinisothiocyan
fitc
conjug
rabbitanti
cat
immunoglobulin
nordic
immunolog
laboratori
tilburg
netherland
ad
well
incub
min
c
humidifi
chamber
slide
wash
dri
coverslip
pb
kaiser
glycerin
ratio
examin
fluoresc
microscop
dilut
show
distinct
fluoresc
signal
onehalf
cell
evalu
posit
reaction
show
posit
signal
design
dubiou
judg
neg
sampl
still
posit
dilut
dilut
twofold
basi
neg
result
obtain
presenc
fcov
rna
faecal
sampl
investig
use
revers
transcriptasepolymeras
chain
reaction
rtpcr
faecal
sampl
frozen
c
analysi
thaw
g
faecal
sampl
homogenis
ml
salin
solut
centrifug
g
min
supernat
remov
filter
use
pore
size
mm
millipor
billerica
usa
three
millilitr
filter
supernat
appli
centricon
column
amersham
bioscienc
piscataway
usa
order
concentr
viral
particl
final
volum
ml
viral
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
milan
itali
reversetranscrib
use
readytogo
youprim
firststrand
bead
kit
amersham
bioscienc
fcov
specif
primer
pmolml
design
herrewegh
et
al
cdna
obtain
describ
amplifi
pcr
use
reaction
mix
compos
ml
cdna
buffer
mm
mgcl
mm
deoxyribonucleotid
triphosph
dntp
u
taq
polymeras
eppendorf
hamburg
germani
mm
primer
primer
herrewegh
et
al
thermal
cycl
protocol
use
follow
c
min
cycl
denatur
c
anneal
c
elong
c
final
elong
step
c
min
assay
neg
control
reaction
mix
without
cdna
posit
control
fcov
cdna
amplifi
vaccin
primucel
fip
pfizer
anim
health
exton
pa
usa
includ
amplicon
run
agaros
gel
visualis
use
ultraviolet
transillumin
base
presenc
absenc
amplicon
cat
classifi
posit
neg
viral
shed
statist
analys
carri
use
specif
softwar
statistica
window
statsoft
inc
tulsa
usa
data
distribut
check
use
kolmogorovesmirnov
normal
test
data
sequenti
sampl
group
analys
use
analysi
varianc
anova
test
repeat
measur
follow
tukey
honest
signific
differ
test
case
nonnorm
distribut
data
correspond
nonparametr
friedman
test
percentag
shedder
sequenti
faecal
sampl
catteri
compar
use
cochran
q
test
possibl
correl
fcov
antibodi
titr
agp
concentr
investig
use
spearman
correl
test
cat
group
b
show
clinic
sign
laboratori
chang
consist
fip
anaemia
lymphopenia
increas
globulin
andor
gglobulin
system
inflammatori
diseas
throughout
studi
period
nevertheless
two
episod
fip
confirm
postmortem
examin
occur
catteri
week
sampl
time
point
two
anim
affect
month
sampl
time
point
one
cat
affect
faecal
shed
fcov
spf
cat
group
cat
catteri
endem
fcov
infect
group
faec
sampl
spf
cat
neg
fcov
genom
cat
group
yield
posit
result
least
one
sampl
tabl
specif
five
cat
cat
posit
sampl
remain
five
neg
least
one
sampl
percentag
shedder
vari
among
sampl
p
sampl
posit
first
five
sampl
wherea
sampl
posit
sampl
success
sampl
sampl
posit
fig
serum
sampl
spf
cat
group
neg
fcov
antibodi
nonsymptomat
cat
catteri
fluctuat
fcov
antibodi
titr
rang
valu
record
catteri
alway
low
usual
rare
peak
tabl
valu
record
sampl
cat
group
median
interquartil
rang
significantli
higher
p
record
sampl
cat
group
although
median
valu
antibodi
titr
group
higher
sampl
compar
sampl
signific
differ
differ
sampl
detect
group
p
mostli
due
high
individu
variabl
fig
similarli
signific
differ
sequenti
sampl
observ
group
p
p
serum
agp
level
spf
cat
low
serum
agp
level
tabl
show
fluctuat
agp
concentr
differ
sampl
time
p
contrari
agp
concentr
cat
group
variabl
differ
sampl
fig
specif
differ
sequenti
sampl
statist
signific
group
p
higher
valu
sampl
agp
concentr
increas
compar
valu
record
sampl
six
cat
group
p
p
agp
concentr
blood
spf
cat
group
median
interquartil
rang
significantli
lower
p
concentr
sampl
obtain
group
fcov
antibodi
titr
serum
agp
level
obtain
catteri
cat
shed
fcov
sampl
significantli
differ
record
cat
result
neg
least
one
faecal
sampl
group
serum
agp
level
statist
correl
fcov
antibodi
titr
nevertheless
data
two
paramet
plot
togeth
fig
evid
group
valu
show
tendenc
increas
sampl
week
occurr
outbreak
fip
catteri
aim
studi
investig
possibl
correl
serum
agp
level
fcov
statu
nonsymptomat
cat
latter
investig
evalu
antifcov
antibodi
titr
andor
faecal
shed
fcov
spf
cat
cat
catteri
differ
level
fcov
infect
unfortun
fcov
shed
individu
cat
could
assess
one
catteri
group
taken
togeth
result
epidemiolog
serolog
andor
faecal
shed
allow
us
classifi
catteri
high
preval
group
low
preval
group
fcov
infect
low
number
fip
case
record
past
neg
result
pcr
fcov
genom
perform
refer
veterinarian
persist
low
antibodi
titr
record
studi
indic
low
rate
fcov
infect
group
although
seroneg
shedder
report
meli
et
al
viral
load
usual
correl
antibodi
titr
gut
et
al
cat
group
classifi
fcov
shedder
addi
jarrett
although
alway
posit
faecal
shed
percentag
differ
report
studi
cite
classifi
shedder
persist
recurr
shedder
cat
respect
differ
might
depend
differ
level
contamin
catteri
fcov
differ
genet
pattern
cat
foley
pedersen
differ
pcr
protocol
introduc
concentr
step
might
increas
sensit
method
emphasis
howev
cat
studi
addi
jarrett
hous
individu
current
studi
cat
share
common
environ
allow
us
rule
recurr
reinfect
like
caus
persist
posit
faecal
pcr
percentag
shedder
decreas
sampl
perform
week
episod
fip
sampl
process
protocol
reagent
unlik
decreas
repres
methodolog
problem
base
data
howev
possibl
establish
direct
causeeeffect
decreas
occurr
fip
catteri
known
faecal
viral
shed
fluctuat
fcovendem
catteri
even
absenc
clinic
fip
case
addi
jarrett
addi
et
al
meli
et
al
accord
susceptibleinfectivesuscept
si
model
infect
propos
foley
et
al
accord
model
antibodi
titr
also
fluctuat
fcovendem
catteri
observ
current
studi
group
serum
agp
level
spf
cat
studi
lower
report
control
cat
includ
previou
studi
duthi
et
al
kajikawa
et
al
control
sera
howev
collect
nonspf
cat
like
expos
sever
antigen
stimuli
kristensen
barsanti
contrast
nonsymptomat
fcov
cat
agp
level
similar
previous
report
although
exclud
increas
serum
agp
concentr
might
trigger
nonspecif
inflammatori
stimuli
clinic
sign
consist
inflamm
record
studi
result
therefor
confirm
serum
agp
level
fluctuat
time
previous
report
addit
demonstr
fluctuat
greater
catteri
higher
preval
fcov
infect
group
moreov
group
agp
level
increas
sampl
week
occurr
fip
case
catteri
sampl
perform
month
second
episod
fip
differ
agp
respons
sampl
might
depend
differ
time
interv
sampl
occurr
fip
case
fluctuat
agp
level
fcov
antibodi
titr
statist
correl
surpris
induc
differ
mechan
object
evalu
fcov
viral
burden
could
obtain
quantit
rtpcr
faec
blood
would
also
allow
us
detail
inform
possibl
relationship
individu
agp
level
individu
fcov
shed
viraemia
nevertheless
demonstr
antibodi
titr
correl
viral
load
gut
et
al
increas
antibodi
titr
serum
agp
level
record
sampl
suggest
occurr
fip
case
preced
nonsymptomat
cat
increas
viral
load
inflammatori
respons
howev
unclear
whether
respons
evok
higher
viral
load
specif
protect
respons
highli
pathogen
fcov
sequenc
fcov
isol
studi
may
help
answer
question
howev
hypothesi
certain
agp
respons
might
protect
diseas
excit
agp
import
immunomodulatori
function
bori
et
al
vasson
et
al
human
chang
agp
glycosyl
pattern
associ
resist
suscept
viral
diseas
rabehi
et
al
interestingli
agp
isol
cat
fip
hyposialyl
ceciliani
et
al
therefor
postul
cat
catteri
endem
fcov
infect
respond
increas
viral
burden
increas
product
agp
cat
hyposialyl
agp
persist
increas
agp
level
develop
fip
conclus
serum
agp
concentr
fluctuat
clinic
healthi
cat
live
catteri
high
preval
fcov
infect
spf
cat
cat
live
catteri
low
preval
fcov
infect
probabl
repres
nonspecif
respons
increas
viral
burden
turn
associ
high
probabl
fip
outbreak
futur
attempt
clarifi
whether
increas
serum
agp
level
consequ
higher
viral
load
nonmut
fcov
protect
respons
mutat
viral
strain
addit
result
present
studi
suggest
agp
might
use
tool
monitor
fcovehost
interact
fcovendem
catteri
